Why Perfect B Is Evaluating AOD 9604: Our Clinical Perspective We began our internal evaluation of AOD 9604 in response to a consistent pattern we were seeing with patients in our South Florida practice: people who had experienced meaningful fat loss on GLP-1 medications, then plateaued or discontinued due to side effects, and were looking for a next option
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults
Apart from DSePA, our group has also studied the radioprotective activity of another organoselenium compound, dihydroxy-1-selenolane (DHS), which was earlier reported for GPx-like activity under in vitro conditions by Iwaoka and co-workers [93, 94]
Alves, J., Gaspar, H., Silva, J., Alves, C., Martins, A., Teodoro, F., & Pedrosa, R
With BPC 157, corneal transparency was maintained and regained after total debridement of corneal epithelium (Figure 15) and dry eye syndrome in rats when BPC 157 counteracts the damaging effects of lacrimal gland extirpation (Lazic et al., 2005
and Chang, S